Xbrane Biopharma: FDA Resubmission in 2022
Research Note
2022-07-04
14:16
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.
FE
Filip Einarsson
Disclosures and disclaimers